XENE (Xenon Pharmaceuticals) Growth Rank : 0 (As of Apr. 06, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals Growth Rank?

Xenon Pharmaceuticals has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Xenon Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Xenon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (NAS:XENE) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

XP0:Germany

Address

200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8

Website

https://www.xenon-pharma.com

Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.

Executives

Ian Mortimer	director, officer: PRESIDENT & CEO	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Sherry Aulin	officer: Chief Financial Officer	200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W
Gary Patou	director
Elizabeth A. Garofalo	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Steven Gannon	director	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
Sherrington Robin	officer: SVP Bus. & Corp. Development	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Dawn Svoronos	director	C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Gillian Cannon	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Justin D. Gover	director	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Patrick Machado	director	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Simon N. Pimstone	director	200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Christopher John Kenney	officer: Chief Medical Officer	200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W
Andrea Difabio	officer: Chief Legal Officer	BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
James R. Empfield	officer: SVP, Drug Discovery	200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W
Seggern Christopher Von	officer: Chief Commercial Officer	200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W